Merck discontinues blood cancer drug program over benefit-risk concerns
MRK•Merck said it would discontinue development of an experimental drug for certain blood cancers after a review suggested its benefits may not outweigh its risks.
MRK•Merck said it would discontinue development of an experimental drug for certain blood cancers after a review suggested its benefits may not outweigh its risks.
Merck said it would discontinue development of an experimental drug for certain blood cancers after a review suggested the treatment’s benefits may not outweigh its risks.